Rituximab-mediated phagocytosis.

(A) Lymphoma cells (4 MCLs, 4 DLCLs, 4 FLs, 4 SLLs) and 2 NTs were opsonized (black bars) or not (empty bars) by 2 μg/mL rituximab, washed, and incubated with macrophages in RPMI 10% human serum for 2 hours. Phagocytosis is represented as the percentage of phagocytosing macrophages. (B) Inhibition represents pooled data (mean inhibition ± SD) from experiments with FL7, MCL6, NT3 and the same source of macrophages as in panel A, with anti-CD16, anti-CD32, anti-CD64 alone or in combination (CD16 + CD32 + CD64).